Skip to content

Early Detection of Arteriosclerosis

Prospective Observational Cohort Study for Early Detection of Arteriosclerosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00863967
Enrollment
269
Registered
2009-03-18
Start date
2003-10-31
Completion date
2015-10-31
Last updated
2009-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriosclerosis, Atherosclerosis, Diabetes Mellitus, Myocardial Infarction, Peripheral Arterial Occlusive Disease, Stroke

Keywords

physical examination, diagnostic techniques and procedures, diagnosis, immunologic tests, diagnostic tests, causality, genetic test, biomarker

Brief summary

Arteriosclerosis is a common chronic disease with well known risk factors like diabetes mellitus, hypertension, dyslipidemia, adipositas and smoking, leading to severe complications like myocardial infarction, stroke or peripheral arterial occlusive disease. In addition to life-style factors there is also a genetic predisposition to develop complicated atherosclerosis. Objective: Improve individual risk prediction by clinical phenotyping and genotyping.

Detailed description

About 300 patients who are treated for various conditions at the department of general medicine at our hospital will be included prospectively in the study. This observational cohort will be followed for at least 10 years follow-up examinations. At baseline and during follow up visits detailed clinical phenotyping is planned (medical and family history,standardized clinical and physical examinations, lab, RX, ECG, stress-test or echocardiogram). The genotyping is performed by DNA-isolation from leucocytes collected at baseline.

Interventions

None listed

Sponsors

Kantonsspital Baselland Bruderholz
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years and older * informed consent

Exclusion criteria

* life-threatening disease * life expectancy \< 1 month * uncapable to provide informed consent

Design outcomes

Primary

MeasureTime frame
Cardiovascular events10 years at least

Secondary

MeasureTime frame
Disease activity score2 / 5 / 10 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026